LUND, SE / ACCESS Newswire / April 20, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that ...

Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April 20 ...

The Best Deep Plane Facelift is done by Dr. Alberico Sessa in Florida SARASOTA, FL / ACCESS Newswire / April 20, 2026 / Interest in advanced facial rejuvenation continues to grow as patients are ...

A 4/20 Message From MMJ Leadership"April 20 has always been a day about access," said Duane Boise, President & CEO of MMJ International Holdings."Now it needs to become a day about standards.

SAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced ...

Insights derived from one of the largest datasets with over 250 million harmonized variant calls from over 8,000 tumor-normal ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ...

(PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven squamous cell NSCLC patients (ORR 43%)Five confirmed PRs among 19 response-evaluable ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...

Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...

The settlement will provide funding to state and local governments nationwide to support recovery efforts related to the ...

Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial investigating nadunolimab in combination with immune-checkpoint ...